Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia
Assessment of of the biological effects of curcumin on microbiota in children with acute lymphoblastic leukemia
Acute Lymphoblastic Leukemia, Pediatric
DRUG: Curcumin|DIETARY_SUPPLEMENT: Standard of Care
Determine the Safety of curcumin in pediatric patients with ALL., Percentage of patients who developed adverse event, 4 weeks
Assessment of the safety of curcumin, which is the most active constituent of the ground rhizome of the Curcuma longa plant, in children with acute lymphoblastic leukemia patients (ALL) in maintenance phase of chemotherapy through the assessment of the any reported adverse event (AE). And assessment of the curcumin effect on health by eliminating intestinal microflora dysbiosis